Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Green Cross Obtains South Korean Approval For BioCryst Influenza Therapy Peramivir

This article was originally published in The Pink Sheet Daily

Executive Summary

The deal is part of a drive to secure anti-influenza options beyond Roche and GSK products in preparation for the next round of global influenza.

You may also be interested in...



Shionogi Looks Beyond Crestor to HIV Platform

TOKYO - Shionogi still has a few years to reap the benefits of Crestor royalties from AstraZeneca, but the looming generic substitution of rival Lipitor is forcing the company to prepare for a slowdown of its blockbuster drug. But according to Macquarie Equities Research, revised ex-U.S. Crestor prospects, strong pipeline prospects and recent launches could position Shionogi well in the near term

Korea FDA Allows Emergency Use Of Intravenous Peramivir for Seriously Ill A/H1N1 Patients

SEOUL - For the first time in its fight against A/H1N1, the Korea Food & Drug Administration allowed the use of injectable antiviral peramivir in a seriously-ill patient even though the product is not yet approved in South Korea

Korea's Green Cross Seeks To Unveil Injectable Flu Antiviral Peramivir Even Before KFDA Approval

SEOUL - With or without an approval from Korea FDA, South Korea's vaccine producer Green Cross is gearing up to launch its version of injectable antiviral peramivir, which was developed by BioCryst Pharmaceuticals for treatment of influenza

Topics

UsernamePublicRestriction

Register

GB140150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel